Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three medications used to treat respiratory conditions: - **Albuterol**: A short-acting beta-2 adrenergic receptor agonist (SABA) that works by relaxing the muscles in the lungs to open up airways - **Ipratropium**: A short-acting muscarinic antagonist (SAMA) that prevents airways from tightening - **Hydrocortisone**: A corticosteroid that reduces inflammation While albuterol and ipratropium are commonly combined in products like Combivent Respimat for COPD treatment, the addition of hydrocortisone (a systemic corticosteroid) represents a comprehensive approach to treating acute respiratory conditions by combining bronchodilation with anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albuterol + hydrocortisone + ipratropium.